Andexanet alfa 200mg powder for solution for infusion vials
NHS hospitals in England used £19,613,700 of indicative cost of Andexanet alfa 200mg powder for solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 19.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Andexanet alfa 200mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Andexanet alfa 200mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Univ Hpl B/Ham Nhs Foundation Trust | £1,184,925 |
| Western Sussex Hospitals Nhs Found Trust | £566,100 |
| Aintree University Hospital Nhs Ft | £549,450 |
| University Hpls Of Leicester Nhs Trust | £510,600 |
| Gloucestershire Hpls Nhs Foundation Trst | £482,850 |
| Maidstone And Tunbridge Wells Nhs Trust | £435,675 |
| Southend Univ Hosp Nhs Foundation Trust | £432,900 |
| London North West Healthcare Nhs Trust | £419,025 |
| Sherwood Forest Hospitals Nhs Trust | £366,300 |
| Sandwell And West Birmingham Hpls Trust | £360,750 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.